

Evaluating the Impact of a Pilot Structured Antimicrobial Stewardship Prospective Audit and Feedback Program in Emergency General Surgery in a Community Hospital



April Chan¹, Rosane Nisenbaum²⁻⁴, Melanie Tsang^{1,2}, Bradley Langford^{2,5,6}, Michael Wan¹, Mark Downing^{1,2}

¹ St. Joseph's Health Centre, Unity Health Toronto, ON Canada, ² University of Toronto, ON Canada, ³ Li Ka Shing Knowledge Institute, Toronto, ON, Canada, ⁴ Applied Health Research Center and MAP Center for Urban Solutions, Toronto, ON Canada, ⁵ Ontario Agency for Health Protection and Promotion, ON Canada, ⁶ Hotel Dieu Shaver Health and Rehabilitation Centre, St. Catharines, ON Canada

Introduction

- Prospective audit and feedback (PAF) is an established antimicrobial stewardship strategy in critical care settings but not in the surgical population.
- We piloted once-weekly structured face-to-face PAF with the Acute Care Surgery (ACS) service from November 23, 2015 to April 29, 2019 in a university-affiliated community hospital.
- These structured fact-to-face PAF sessions were facilitated by the Antimicrobial Stewardship Program (ASP) pharmacist and attended by the ACS surgeons and the ASP physician. Sessions lasted 10-15 minutes and all patients under the ACS service on systemic antimicrobials were discussed.
- Usual Care at our community hospital comprised of ad-hoc PAF on targeted antimicrobials once or twice weekly with recommendations made to ACS surgeons using written or verbal methods (latter included face-to-face or telephone).
- Outcomes using structured face-to-face PAF compared to ad-hoc PAF (Usual Care) were evaluated.

Methods

- The structured PAF study period was from August 1, 2017- April 30, 2019 while the ad-hoc PAF study period was from May 1, 2019-January 31, 2021.
- The primary outcome was antimicrobial usage measured in Days of Therapy/1000 patient days (DOT/1000-PD) for all systemic and targeted antimicrobials ordered by the ACS team. Targeted antimicrobials included 3rd generation cephalosporins, piperacillin/tazobactam, carbapenems, fluoroquinolones and clindamycin.
- Secondary outcomes included *C. difficile* infections, length of stay and readmission within 30 days.
- Interrupted time series segmented negative binomial regression analysis was used to evaluate the change in the primary outcome.
- The first two secondary outcomes were analyzed using a logistic regression model while a negative binomial regression model was used to evaluate readmission within 30 days.

Figure 1: Primary Outcome in DOT/1000-PD





Figure 2: Predicted rates by time using negative binomial models



Results

Table 1: Interrupted Time Series Analysis of Primary Outcome

| | Rate Ratio | 95% CI | p-value | | |
|-------------------------|------------|-----------|---------|--|--|
| All Antimicrobials | | | | | |
| Change in Level | 0.85 | 0.70-1.02 | 0.074 | | |
| Change in Trend | 0.99 | 0.98-1.01 | 0.209 | | |
| Targeted antimicrobials | | | | | |
| Change in Level | 0.91 | 0.62-1.33 | 0.634 | | |
| Change in Trend | 0.99 | 0.96-1.02 | 0.664 | | |

Table 2: Secondary Outcomes

| | Structured PAF N=776 | Ad-hoc PAF N=783 | Odds ratio or Rate ratio (95% CI) | p-value |
|---|----------------------------|------------------------|-----------------------------------|---------|
| | | | | |
| Readmission within 30 days (n, %) | | | | |
| Yes | 45 (5.6) | 40 (5.0) | 0.87 (0.56-1.35) | 0.5457 |
| No | 753 (94.4) | 766 (95.0) | | |
| | | | | |
| C. difficile Infection (n, %) | | | | |
| Yes | 3 (0.4) | 2 (0.3) | 0.66 (0.06-5.77) | 0.9906 |
| No | 795 (99.6) | 804 (99.8) | | |
| | | | | |
| Length of Stay (Days) | | | | |
| Mean (standard deviation) | 2.7 (3.5) | 2.9 (5.0) | 1.07 (0.98-1.17) | 0.1206 |
| Median (interquartile range) | 2 (1-3) | 2.0 (1-3) | | |

Conclusion

Structured PAF showed similar clinical outcomes to ad-hoc PAF for the Acute Care Surgery Service at our institution. Other antimicrobial stewardship interventions can be explored to better support judicious antimicrobial use in General Surgery.

Contact Information:
April Chan
april.chan@unityhealth.to

